| Promising efficacy of oral nano-silymarin formulation on prevention of vancomycin-induced nephrotoxicity: a randomized, triple-blinded, placebo-controlled clinical trial 2026 · nano-silymarin · Patients receiving vancomycin for infection and at risk of vancomycin-induced nephrotoxicity | 140 mg | 2 weeks | — |
| Evaluation of the effect of Silybum marianum extract on menopausal symptoms: A randomized, double-blind placebo-controlled trial 2020 · S. marianum extract · Women with hot flashes and menopausal symptoms; age not reported | 400 mg | 12 weeks | 40 |
| Effect of Oral Silymarin Administration on Prevention of Radiotherapy Induced Mucositis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial 2016 · silymarin group · Patients with head and neck cancer receiving radiotherapy | 420 mg | 6 weeks | — |
| Silymarin in combination with hair follicle transplantation as a potential treatment for refractory vitiligo: A double-blind randomized controlled trial 2024 · Silymarin plus hair follicle transplantation · Adults aged 18–59 with stable, non-segmental refractory vitiligo | 140 mg | 90 days | 10 |
| The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus 2016 · B. aristata/S. marianum (Berberol) · Patients with type 1 diabetes mellitus | 210 mg | 26 weeks | — |
| The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial 2006 · silymarin group · People with type II diabetes | 600 mg | 120 days | 25 |
| Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men 2013 · selenium-silymarin group · Men with lower urinary tract symptoms and benign prostatic hyperplasia, with PSA ≤2.5 ng/ml | 570 mg | 26 weeks | 26 |
| The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy - a six month placebo-controlled double-blind clinical trial 2010 · SM-Se group · Men 2–3 months after radical prostatectomy | 570 mg | 26 weeks | 19 |
| A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis 2009 · silymarin group · Patients aged 13 years or older with symptomatic acute hepatitis and ALT greater than 2.5 times the upper limit of normal | 420 mg | 4 weeks | 55 |
| Immunomodulatory effects of silymarin in patients with β-thalassemia major 2013 · combined therapy group · Patients with β-thalassemia major | 420 mg | 12 weeks | 25 |
| A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL) 2010 · Milk thistle (MT) group · Children aged 1–21 years with acute lymphoblastic leukemia in the maintenance phase of chemotherapy and grade 2 or greater hepatic toxicity | 240 mg | 4 weeks | 24 |
| Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial 2015 · silymarin treatment group · Patients aged 25–50 with type 2 diabetes mellitus on stable medication | 420 mg | 45 days | 20 |
| Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial 2018 · silymarin group · Men and women aged 25–50 with type 2 diabetes mellitus on stable medication | 420 mg | 45 days | 20 |
| Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial 2022 · silymarin group · Patients with non-metastatic breast cancer receiving the AC-T chemotherapy regimen | 420 mg | 30 days | 15 |
| Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial 2009 · Silymarin group · Patients with beta-thalassemia major | 420 mg | 90 days | — |
| Adjunctive silymarin supplementation and its effects on disease severity, oxidative stress, and inflammation in patients with Alzheimer's disease 2024 · case group · Patients with Alzheimer's disease confirmed by DSM-5 criteria and brain imaging; age and sex not stated | 450 mg | 90 days | — |
| Evaluation of oral silymarin formulation efficacy in prevention of doxorubicin induced hepatotoxicity in patients with non-metastatic breast cancer 2025 · silymarin group · Patients with non-metastatic breast cancer receiving doxorubicin-containing chemotherapy | 420 mg | 9 weeks | — |
| Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C 2011 · 280 mg silymarin · Adults with noncirrhotic nonalcoholic fatty liver disease or hepatitis C | 840 mg | 7 days | — |
| The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex®) in patients with apparent risk factors for nonalcoholic steatohepatitis: a phase II, multicentered, randomized, double-blind, placebo-controlled clinical trial 2025 · high-dose Heptex® · Adults aged 18–65, both sexes, with elevated liver enzymes, steatosis and F1/F2 fibrosis scores; apparent risk factors for NASH | 300 mg | 36 weeks | 44 |
| The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex®) in patients with apparent risk factors for nonalcoholic steatohepatitis: a phase II, multicentered, randomized, double-blind, placebo-controlled clinical trial 2025 · low-dose Heptex® · Adults aged 18–65, both sexes, with elevated liver enzymes, steatosis and F1/F2 fibrosis scores; apparent risk factors for NASH | 300 mg | 36 weeks | 41 |
| Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans 2006 · Milk thistle · Healthy young adults; 8 women and 8 men, mean age 26 years | 900 mg | 2 weeks | 16 |
| The iron-chelating potential of silybin in patients with hereditary haemochromatosis 2010 · Silybin · Adults with HFE-related hereditary haemochromatosis, 9 male and 1 female, with grade 4 siderosis and fibrosis or cirrhosis | 140 mg | 1 day | 10 |
| Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 2013 · Berberis aristata/Silybum marianum extract · Dyslipidemic, euglycemic patients | 210 mg | 26 weeks | — |
| Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses 2015 · B. aristata/S. marianum · Adults with dyslipidemia who had experienced adverse events while taking high-dose statins and tolerated a half-dose statin | 210 mg | 26 weeks | — |
| Superior silybin bioavailability of silybin-phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers 2019 · Conventional SM tablets · Healthy men and women aged 18–44 years | 70 mg | 1 day | 23 |
| Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C 2011 · 560 mg silymarin · Adults with noncirrhotic nonalcoholic fatty liver disease or hepatitis C | 1.68 g | 7 days | — |
| Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial 2017 · Berberol K · Adults aged 18 or older, either sex, with low cardiovascular risk, hypercholesterolemia, overweight, and normal blood pressure | 105 mg | 90 days | 73 |
| A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis 2017 · silymarin group · Adults with biopsy-proven nonalcoholic steatohepatitis (NASH) and a NAFLD activity score of 4 or more | 2.1 g | 48 weeks | 49 |
| Silymarin, Olibanum, and Nettle, A Mixed Herbal Formulation in the Treatment of Type II Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial 2017 · Herbal Formulation · Adults aged 40–60 with type II diabetes mellitus | 600 mg | 90 days | 30 |
| Phytoestrogens/insoluble fibers and colonic estrogen receptor β: randomized, double-blind, placebo-controlled study 2013 · active dietary intervention (ADI) · Patients with previous sporadic colonic adenomas scheduled for surveillance colonoscopy | 350 mg | 60 days | — |
| A Randomized Controlled Trial of a Herbal Compound for Improving Metabolic Parameters in Diabetic Patients with Uncontrolled Dyslipidemia 2019 · intervention group · Adults with type 2 diabetes and dyslipidemia despite statin therapy; age and sex not specified | 1 g | 12 weeks | 25 |